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Primary biliary cirrhosis (PBC) is presumed to be
an autoimmune disease of the liver with aber-
rant cellular and humoral immune responses
characterized by granulomatous destruction of
the interlobular bile ducts leading to progressive
ductopenia, slowly progressing cholestasis, fi-
brosis and eventually liver failure.1 Where there
is an increased risk for hepatocellular carcinoma
and extrahepatic malignancy in PBC remains
controversial.2 On the other hand, autoimmune
diseases were associated with an increased inci-
dence of lymphoproliferative disorders derived
from B cells.3 Case reports on such associations
have been described for PBC patients in the past.4
Herein, we describe a patient with PBC and mul-
tiple myeloma (MM). Both conditions responded
well to the vincristine, adriamycin and dexa-
methasone (VAD) treatment protocol followed
by oral alkylating chemotherapy. Thus, we specu-
lated on the possible relationship between these
two entities.
Case Report
A 52-year-old man, a heavy smoker (25 pack
years), presented with weakness, pruritis, weight
loss and back pain that had first occurred 5 years
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Patients with primary biliary cirrhosis (PBC) are at increased risk for various malignancies including lym-
phoproliferative diseases. In this report, we describe a 52-year-old man with the simultaneous diagnosis
of PBC and IgG-kappa multiple myeloma (MM). Serum cholestatic enzyme (alkaline phosphatase and
gamma-glutamyltransferase) levels decreased after three courses of vincristine, adriamycin and dexametha-
sone treatment followed by six courses of melphalan and methylprednisolone, given for MM. Pruritus also
disappeared. He did not show any progression during the next 24 months of clinical follow-up. The coex-
istence of PBC and MM is rare and the pathogenetic mechanism under this association remains unclear.
Clinical improvement of both diseases in this patient after chemotherapy may indicate an association; how-
ever, absence of concurrency in previous large series increases the possibility of coincidence in this case.
When compared with the previous single case reports, this case provided long-term results about response
after chemotherapy. [J Formos Med Assoc 2008;107(2):185–190]
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previously. His back pain was persistant and was
present even at rest. He had lost nearly 10% of
his total body weight. Physical examination was
unremarkable except for mild painless he-
patosplenomegaly. On laboratory examination,
erythrocyte sedimentation rate was 80 mm/hr,
complete blood cell count showed hemoglobin
9.9 g/dL, hematocrit 31%, mean corpuscular vol-
ume 96.9 fL, total leukocytes 5000/mm3, neu-
trophils 2100/mm3, lymphocytes 2200/mm3,
monocytes 600/mm3 and platelets 139,000/mm3.
Serum biochemical analysis showed alanine
aminotransferase 116 U/L, aspartate aminotrans-
ferase 137 U/L, alkaline phosphatase (ALP)
1658 U/L, gamma-glutamyltransferase (GGT)
413 U/L, total bilirubin 93.88 µmol/L and direct
bilirubin 44.12 µmol/L.
Abdominal ultrasonography revealed homo-
geneous increase in the liver parenchymal echo-
geneity with normal intrahepatic and extrahepatic
bile ducts. Liver biopsy revealed destruction of the
septal and interlobular bile ducts together with
inflammatory infiltration of mononuclear cells,
obliteration of the biliary canaliculi and portal
septal fibrosis (Figure 1). Antimitochondrial an-
tibody (AMA) was positive at 1:160 dilution.
Antinuclear antibody, anti-smooth muscle anti-
body, anti liver-kidney microsomal antibody-1
and serologic markers for hepatitis B and C viruses
were negative. Serum IgM level was 6.43 g/L
(normal, 0.50–0.90 g/L). PBC was diagnosed.
Grade 1–2 esophageal varices with features of
portal hypertensive gastropathy were found using
upper gastrointestinal endoscopy. Ursodeoxy-
cholic acid (1 g/day) and propranolol (40 mg/day)
were given perorally. Serum protein electrophore-
sis showed a monoclonal band (36.2 g/L) and
IgG-kappa type monoclonal paraproteinemia
was found in serum immunofixation electropho-
resis (Figure 2). Skeletal X-rays showed punched-
out lesions in the calvarial bones and destruction
in the 8–10th thoracic vertebral corpuses with gen-
eralized osteopenia. Bone marrow biopsy revealed
an increased number of atypical plasma cells
(30%) with monotypic IgG and kappa light
chain secretion (Figures 3 and 4). Serum beta-2
microglobulin level was 6 mg/dL (normal,
0–2.5 mg/dL). The diagnosis was MM of IgG-
kappa type.
Emergency radiotherapy (total dose, 2500 rad)
was performed to his thoracic vertebrae. The VAD
protocol (vincristine 0.4 mg/day and adriamycin
15 mg/day on days 1–4 together with oral dexa-
methasone 40 mg/day on days 1–4, 9–12 and
17–20) was chosen as remission induction ther-
apy with an intravenous bisphosphonate, zole-
dronate (4 mg/month). After three VAD courses,
the pruritus disappeared, his hemoglobin level
increased to 10.9 g/dL, and serum monoclonal
band decreased to 50% of the basal level
(36.2 g/L to 19.4 g/L). Control serum beta-2 mi-
croglobulin level was 3.55 mg/dL. Although he-
patic cholestatic enzyme levels remained elevated
during ursodeoxycholic acid treatment alone, a sig-
nificant decrease was achieved after three success-
ful VAD courses (ALP 625 IU/L, GGT 313 IU/L,
serum IgM 0.94 g/L, total bilirubin 17.3 µmol/L,
direct bilirubin 11.2 µmol/L).
After partial remission was achieved with VAD
treatment, another three courses were planned.
However, he refused any inpatient treatment.
Then, six courses of melphalan (14 mg/day for 
4 days every 4 weeks) and methylprednisolone
(100 mg/day for 4 days every 4 weeks) treatment
was given. He did not show any progression 
over the next 24 months of clinical follow-up.
However, his MM later relapsed, and thalidomide
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Figure 1. Inflammatory infiltration of the portal area with
mononuclear cells resulting in destruction and obliteration
of the biliary canaliculi and fibrosis (hematoxylin & eosin,
100×).
400 mg/day with high-dose dexamethasone was
given (Figure 5). His last biochemical analysis re-
vealed serum monoclonal band 17.3 g/L, ALP
680 IU/L, GGT 289 IU/L, total bilirubin 19.41
µmol/L and direct bilirubin 13.31 µmol/L.
Discussion
An increased incidence of malignant lympho-
proliferative transformation has been described in
patients with autoimmune disorders such as rheu-
matoid arthritis, systemic lupus erythematosus,
Sjögren’s syndrome, and autoimmune thyroid dis-
ease.5 It has been suggested that PBC patients
with secondary Sjögren’s syndrome are associated
with an increased risk of lymphoproliferative
diseases.4 Rarely has the association of MM with
PBC been reported in the past (Table).6–13 The
median age of these patients was 60 years (range,
48–71 years), and there was no significant gender
predominance (male/female, 4/5). They are dif-
ferent from PBC patients, in whom there is sig-
nificant female predominance.14 The male to
female ratio is about 1.45 in MM.15 Together with
our patient, four of nine patients had IgG-kappa
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Figure 2. Serum protein electrophoresis shows M-spike in the gamma-globulin band. Serum immunoelectrophoresis 
revealed IgG-kappa type monoclonal paraproteinemia.
Figure 3. Trephine biopsy section shows infiltration of bone
marrow with atypical plasma cells (hematoxylin & eosin,
400×).
Figure 4. Kappa light chain immunoreactivity in atypical
plasma cells (AEC chromagen, 400×).
paraproteinemia (45%), three had IgG-lambda
(33%), one had IgA-kappa (11%), and one had
lambda light chain Bence-Jones proteinuria
(11%). In most of the patients (89%), both dis-
eases were diagnosed simultaneously, except for
one patient in whom MM occurred later during
the clinical follow-up of PBC.
In autoimmune diseases, abnormalities of im-
mune function such as existence of serum autoan-
tibodies and/or circulating immune complexes,
polyclonal elevations in serum immunoglobulin
levels and association with other autoimmune
disorders are not unusual. According to that, both
cellular and humoral abnormalities have been
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Figure 5. The patient’s clinical course: serum biochemical parameters (alkaline phosphatase [ALP], gamma-
glutamyltransferase [GGT] and M-spike) during the follow-up period.











1 48 F IgG, lambda Simultaneous No response No response I II-A 6
to treatment 
(death due to 
hepatic coma)
2 64 F IgG, kappa Simultaneous Partial remission Positive response II II-A 7
to treatment
3 66 M IgG, lambda MMPBC Partial remission Unknown I–II II-A 8
(death due to 
sepsis)
4 65 M IgA, kappa Simultaneous Refused treatment Refused treatment – III-B 9
(death due to 
pneumonia)
5 60 M IgG, kappa Simultaneous Partial remission Improvement in I III-A 10
immunologic markers
6 55 F BJP, lambda Simultaneous Partial remission Positive response II II-A 11
to treatment
7 71 F IgG, lambda Simultaneous – Unknown II–III II-A 12
8 59 F IgG, kappa Simultaneous Partial remission Positive response III I-A 13
to treatment
9 52 M IgG, kappa Simultaneous Partial remission Positive response I–II III-A This case
to treatment
BJP = Bence-Jones proteinuria.
observed among patients with PBC.16 Van de
Water et al first demonstrated T cell clones (CD4+
and CD8+) reacting with the E2 subunit of pyru-
vate dehydrogenase multienzyme complex (PDC-
E2) located within the inner lining of the
mitochondria of biliary epithelial cells in PBC
patients.17 Activated B lymphocytes, increased in
the peripheral blood of PBC patients in response
to T cells, secrete polyclonal AMA (anti-M2) in
95% of cases.18 The predominant immunoglobu-
lin subtypes of AMA have been identified as IgG1
and IgG3, and polyclonal elevations of IgM appear
most commonly in PBC.17,18 Errors in activating
IgG synthesis or abnormal T cell suppressor ac-
tivity have been hypothesized as reasons for this
discrepancy.
The increased incidence of malignant lym-
phoproliferative diseases noted in autoimmune
diseases has also been reported for PBC in 
different studies.3,4 The longstanding polyclonal 
hypergammaglobulinemia in PBC is attributed
to several immune dysfunctions such as defects
in hepatic clearance of antigens, immunologic
imbalance between suppressor and helper T cells,
and continuing B cell activation in response to 
T cells. Additional genetic events may contribute
to the development of lymphoproliferative dis-
eases.18 Moreover, interleukin (IL)-6 (a known 
B cell growth factor or hybridoma growth factor
suggesting the contribution of Th2 T cells) also
increased in the bile ducts of PBC patients.19 IL-6
is the most important proliferating and survival
factor in myeloma.20 On the other hand, benign
monoclonal gammopathy can rarely be seen
with PBC.16 Lymphoproliferative malignancies
occasionally arise in patients with longstanding
benign monoclonal gammopathy. Forty-six (19%)
of the 241 patients with benign monoclonal
gammopathy developed plasma cell malignancy
during the 10-year follow-up in a Mayo Clinic
study.21 A majority (70%) of the patients were 
reported to have MM.
The coexistence of PBC and MM is a rare con-
dition and the pathogenetic mechanism of this
association remains unclear. Could PBC build 
a facilitating circumstance for MM? Immunogenic
stimulation and/or impairment stemming from
chronic antigenic stimulation may play a role.
However, Moran et al evaluated the clinical and
biochemical characteristics of 80 PBC patients and
only one patient had a concurrent diagnosis of
MM.22 Furthermore, no MM patient had been re-
ported in two other studies that had reviewed sepa-
rate large PBC databases.2,23 These findings weaken
the possibility of any temporal relationship.
The clinical course of our patient in the last 
5 years is summarized in Figure 5. PBC activity
seemed to improve with myeloma treatment
(Figure 5). Washio et al,7 Amakasu et al,10 Akashi
et al11 and Lazzaro et al13 (Table) also reported
similar findings after treatment with melphalan
and methylprednisolone. We gave three different
chemotherapy protocols to our patient in the
follow-up period: VAD, melphalan + methyl-
prednisolone and thalidomide + dexamethasone.
All of them included high-dose corticosteroids as
in the treatment protocols of previous patients,
which were known to have somewhat beneficial
effects on PBC.24 Improvement in the cholestatic
liver enzymes of this patient might have been
due to the high-dose corticosteroids. Although
the clinical activities of both diseases seemed to
be parallel in this patient, it is difficult to suggest
a causal relationship between them with the
available data.
In conclusion, algorithmic analysis of a serum
monoclonal paraprotein band in a PBC patient
can lead to the diagnosis of a malignant plasma
cell dyscrasia. Serum immunoelectrophoresis in
our patient showed IgG and kappa monoclonal
bands. Increased serum IgM fraction was
polyclonal and possibly located under the beta-
globulin band (10 g/L) in the protein elec-
trophoresis (Figure 2). The association between
MM and PBC has not been defined in any large
series reported in the literature. There is a need to
gather the unique case experiences and prospective
studies for a wider knowledge and better under-
standing of the pathogenesis of this association if
it exists. There are no such data available from
previous retrospective studies. When compared
with previous reports, this case provides long-term
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results about the response after chemotherapy
and maintenance of the response related with
myeloma. Although such an association is rare,
these findings can help physicians to form ideal
treatment strategies for future cases.
References
1. Gershwin ME, Mackay IR. Primary biliary cirrhosis: para-
digm or paradox for autoimmunity. Gastroenterology 1990;
99:822–33.
2. Nijhawan PK, Therneau TM, Dickson ER, et al. Incidence
of cancer in primary biliary cirrhosis: the Mayo experience.
Hepatology 1999;29:1396–8.
3. Ehrenfeld M, Abu-Shakra M, Buskila D, et al. The dual as-
sociation between lymphoma and autoimmunity. Blood
Cells Mol Dis 2001;27:750–6.
4. Hahn JS, Kim C, Min YH, et al. Non-Hodgkin’s lymphoma
and primary biliary cirrhosis with Sjögren’s syndrome.
Yonsei Med J 2001;42:258–63.
5. Shoenfeld Y, Gershwin ME, eds. Cancer and Autoimmunity.
Amsterdam: Elsevier Science, 2000:1–446.
6. Blade J, Montserrat E, Bruguera M, et al. Multiple myeloma
in primary biliary cirrhosis. Scand J Haematol 1981;26:
14–8.
7. Washio M, Tsuji H, Murai K, et al. A case of asymptomatic
primary biliary cirrhosis associated with multiple myeloma
and atrophic thyroiditis. Nippon Naika Gakkai Zasshi 1987;
76:528–32.
8. Fujii H, Yashige H. Multiple myeloma of IgG-lambda type
associated with asymptomatic primary biliary cirrhosis.
Jpn J Clin Hematol 1989;30:1886–91.
9. Kaneko H, Endo T, Saitoh H, et al. Primary biliary cirrhosis
associated with multiple myeloma. Intern Med 1993;
32:802–5.
10. Amakasu H, Kanno A, Abe M. Multiple myeloma occur-
ring in early stage primary biliary cirrhosis. Tohoku J Exp
Med 1993;169:197–203.
11. Akashi Y, Yoshizawa N, Kubota T, et al. Primary biliary 
cirrhosis complicated with Sjögren’s syndrome and 
multiple myeloma. A case report. Nephron 1996;73:
730–2.
12. Rodriguez-Leal GA, Moran-Villota S, Arista-Nasr J, et al.
Case report of multiple myeloma and hypothyroidism in
primary biliary cirrhosis. Rev Invest Clin 1997;49:215–20.
13. Lazzaro A, Bernuzzi P, Arcari A, et al. A singular case of
multiple myeloma and primary biliary cirrhosis strictly 
associated in pathogenesis and response to alkylating
therapy. Am J Hematol 2006;81:557.
14. Selmi C, Invernizzi P, Keeffe EB, et al. Epidemiology and
pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol
2004;38:264–71.
15. Cuzick J. Multiple myeloma. Cancer Surv 1994;19–20:
455–74.
16. Culp KS, Fleming CR, Duffy J, et al. Autoimmune associa-
tions in primary cirrhosis. Mayo Clin Proc 1982;57:365.
17. Van de Water J, Ansari A, Prindiville T, et al. Heterogeneity
of autoreactive T cell clones specific for the E2 component
of the pyruvate dehydrogenase complex in primary biliary
cirrhosis. J Exp Med 1995;181:723–33.
18. Nakamura M, Ishibashi H, Matsui M, et al. Peripheral B
lymphocyte repertoire to mitochondrial antigen in 
primary biliary cirrhosis—positive correlation between
the disease activity and the frequency of circulating B lym-
phocytes specific for pyruvate dehydrogenase complex.
Autoimmunity 1995;21:253–62.
19. Yasoshima M, Kono N, Sugahara H, et al. Increased ex-
pression of interleukin-6 and tumor necrosis factor-α in
pathologic biliary epithelial cells: in situ and culture study.
Lab Invest 1998;78:89–100.
20. Ishihara K, Hirano T. IL-6 in autoimmune disease and
chronic inflammatory proliferative disease. Cytokine Growth
Factor Rev 2002;13:357–68.
21. Keyle RA. Benign monoclonal gammopathy. JAMA
1984;241:1849–55.
22. Moran S, Rodriguez-Leal G, Marin-Lopez E, et al. Primary
biliary cirrhosis: clinical features and survival of a Mexican
population. Rev Gastroenterol Mex 1996;61:212–19.
23. Howel D, Metcalf JV, Gray J, et al. Cancer risk in primary
biliary cirrhosis: a study in northern England. Gut
1999;45:756–60.
24. Oo YH, Neuberger J. Options for treatment of primary 
biliary cirrhosis. Drugs 2004;64:2261–71.
